Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
March 07, 2024 06:00 ET
|
Immuron Limited
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy...
Immuron Presentation Australian Biologics Festival 2024
February 21, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
November 28, 2023 06:33 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite...